Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes.
about
Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activationRisk factors in coronary atherosclerosis athero-inflammation: the meeting pointAssociation between monocyte Fcgamma subclass expression and acute coronary syndromeG-protein-coupled receptor kinase 2 and endothelial dysfunction: molecular insights and pathophysiological mechanismsG protein-coupled receptor kinase 2, with β-arrestin 2, impairs insulin-induced Akt/endothelial nitric oxide synthase signaling in ob/ob mouse aortaDiabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERKAdvanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes.CREB downregulation in vascular disease: a common response to cardiovascular riskEvaluation of mean platelet volume in patients with type 2 diabetes mellitus and blood glucose regulation: a marker for atherosclerosis?Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetesPPARgamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus.Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications.Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides.Worsened arterial stiffness in high-risk cardiovascular patients with high habitual carbohydrate intake: a cross-sectional vascular function study.Cardiovascular disease in diabetes: where does glucose fit in?Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes MellitusLipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitusTroponin in diabetic patients with and without chronic coronary artery disease.MicroRNA-134 Contributes to Glucose-Induced Endothelial Cell Dysfunction and This Effect Can Be Reversed by Far-Infrared Irradiation.Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?The vascular endothelium in diabetes--a therapeutic target?Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function.Atherosclerosis in diabetes and insulin resistance.Salivary lysozyme and prevalent coronary heart disease: possible effects of oral health on endothelial dysfunctionComparison of cardiovascular risk factors for peripheral artery disease and coronary artery disease in the korean population.Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection.Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes.Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A2 and secretory phospholipase A2 in patients with newly diagnosed type 2 diabetesImprovement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus.Use of a glucose management service improves glycemic control following vascular surgery: an interrupted time-series study.Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics.The influence of insulin resistance, obesity, and diabetes mellitus on vascular tone and myocardial blood flow.Interacting with thioredoxin-1--disease or no disease?Gestational diabetes mellitus and cardiovascular risk after pregnancy.The Charcot foot as a complication of diabetic neuropathy.Revascularization for Advanced Coronary Artery Disease in Type 2 Diabetic Patients: Choosing Wisely Between PCI and Surgery.The metabolites in peripheral blood mononuclear cells showed greater differences between patients with impaired fasting glucose or type 2 diabetes and healthy controls than those in plasma.Clinical interaction between diabetes duration and aortic stiffness in type 2 diabetes mellitus.
P2860
Q24653742-83A2FF4E-8901-4C49-9F8E-D41A3AB6F6B5Q24793107-48FED1CF-301A-4A32-BF84-5FA8F412D771Q24804925-E155C875-0119-4F9B-A258-BC9D89D49105Q26786233-140DE510-A371-42EA-B128-542105B21375Q28728953-6D7EE270-F4A6-4427-ADC2-7BF79584BE9DQ28756314-19166D96-AD8B-4CCA-BB5F-42D2CDBFA238Q30518002-D7209CF9-7CB2-4D25-8D23-D9C159D1CB4CQ33344790-61E2C389-534A-4167-A20C-EDD2B20A83C7Q33739408-AB2EEB0A-2086-40F3-9A2D-848FC5D8EE56Q33756264-8B947593-06A1-4026-B2D3-D9490272D02BQ33803486-E140C7FF-BBED-4BAE-A75A-F0A2919F7970Q33811239-06C15E33-D03D-4913-9EB4-D365F90091DDQ33901576-A76FF889-4BAA-498C-B7D5-F3221124100AQ34481884-55D19F26-AAE4-4404-9221-CACC264EADD7Q35100030-C8BD8AF0-A012-400F-B0E6-CEFFDC60F799Q35137148-E6B838E6-CD5C-4E82-B631-BE2D9F5DDB9FQ35323531-62EE5038-A18A-4946-BFC1-7CF5301CD580Q35520145-5110DC59-920E-4CB7-976D-A5A701F99FF4Q35701327-F8FF74E1-DFE9-423B-BDE6-FBF819825B84Q35901547-93CDFF07-51C0-40CD-B57F-14F9AE38F845Q36664118-94E4670D-85CB-462D-B2F6-67AEF04D8E68Q36673550-C9A9553A-ABC1-446C-8BAD-774E0CD5634CQ36737368-CC80EA01-3CB1-4B06-9C9C-AC09BD074ED1Q36857541-4CC4FC69-1037-457D-9CA5-F72513386B44Q36870604-C4481B7B-7280-4AB4-9C2C-07CFC4B3722EQ36909476-B65E997A-B4CC-46EA-A648-3F827B82FC5EQ37076469-5964669F-65FE-47AF-9C39-19C2E07E4DAEQ37082698-8B5F0BFE-06A9-4747-A2BF-FD47E5ACB230Q37403188-DE6D8DFD-CCBE-4118-8B01-7EDE17D94D0FQ37431606-8288452E-49A9-403E-BF43-F267D2A6E02CQ37473215-20DDA50E-7911-458F-A7E4-32C237374499Q37625083-4C08052A-284E-45B1-AFF7-375D2714C7D2Q37645663-170F56A3-655F-4594-85DB-C9CD1A0952B6Q37972078-642DE3BD-B5BE-4737-8923-7EA3CDFBB6D9Q38032332-22DF802E-EF7B-4BBF-BEA9-4D3304225CD2Q38170410-8A785AAC-2758-4410-BE1D-F110342D2254Q38263708-B10AD2E7-87AD-44DE-AB48-F4FC6987D7B7Q38735428-57E87BD9-8122-42B3-B380-531239B60838Q38968337-2B47847D-984C-4220-8621-ABD9016B3605Q39413132-CF5B7B12-3831-4885-B732-2EFD098D2008
P2860
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Prevention Conference VI: Diab ...... f atherosclerosis in diabetes.
@en
Prevention Conference VI: Diab ...... f atherosclerosis in diabetes.
@nl
type
label
Prevention Conference VI: Diab ...... f atherosclerosis in diabetes.
@en
Prevention Conference VI: Diab ...... f atherosclerosis in diabetes.
@nl
prefLabel
Prevention Conference VI: Diab ...... f atherosclerosis in diabetes.
@en
Prevention Conference VI: Diab ...... f atherosclerosis in diabetes.
@nl
P2093
P1433
P1476
Prevention Conference VI: Diab ...... f atherosclerosis in diabetes.
@en
P2093
Alan Chait
Burton Sobel
Eugene Barrett
George King
George Steiner
Helen Vlassara
Jane Reusch
Maria Lopes-Virella
Momtaz Wassef
Robert H Eckel
P304
P356
10.1161/01.CIR.0000013954.65303.C5
P407
P577
2002-05-01T00:00:00Z